GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
Moore
L E
LE
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20852, USA. moorele@mail.nih.gov
Baris
D R
DR
Figueroa
J D
JD
Garcia-Closas
M
M
Karagas
M R
MR
Schwenn
M R
MR
Johnson
A T
AT
Lubin
J H
JH
Hein
D W
DW
Dagnall
C L
CL
Colt
J S
JS
Kida
M
M
Jones
M A
MA
Schned
A R
AR
Cherala
S S
SS
Chanock
S J
SJ
Cantor
K P
KP
Silverman
D T
DT
Rothman
N
N
D000107:Acetylation; D000328:Adult; D000368:Aged; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012306:Risk; D012907:Smoking / Q000009:adverse effects*; D001749:Urinary Bladder Neoplasms / Q000209:etiology* / Q000235:genetics
D001191:Arylamine N-Acetyltransferase; D005982:Glutathione Transferase; C478900:NAT2 protein, human